HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maybelline

This article was originally published in The Rose Sheet

Executive Summary

Third quarter earnings per share will be approximately 25, compared to 36 in the third quarter of 1993, the company says, due to "slower than expected sales growth in the Revitalizing brand, coupled with the continuing trend of retailer inventory reduction." The company says that the factors may also lead to full-year 1994 earnings per share dropping below 1993's year-end figure of $1.25 per share. Maybelline attributes slow Revitalizing sales to display reconfigurations at the retail level that took two to three months longer than anticipated. To compensate, the company plans to add promotional support with couponing and other trial incentives for Revitalizing. The firm also recently launched new television and print ads for the brand. Maybelline notes that it is expanding its ongoing share repurchasing program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel